Eef Dirksen
Head, Analytical Validation & Quality Control Byondis
After obtaining a PhD in biomolecular mass spectrometry in 2006, Eef Dirksen moved to Philips Research and in 2010, he was hired by MSD (Merck) in Oss, The Netherlands, where he managed a team focusing on the characterization of biopharmaceutical proteins. Here, Eef was, involved in the successful late-stage development of Keytruda®.
In 2015, Eef joined Byondis to work on elucidating the in vivo biotransformation of antibody-drug conjugates (ADCs). Currently, he is heading the Department of Analytical Development and Quality Control that is responsible for all analytical activities in support of early-stage CMC development of monoclonal antibodies and ADCs.
Seminars
Wednesday 25th February 2026
Dissecting a Decrease in Cytotoxicity Observed For a Stressed ADC & Assessing Impact on Activity
12:00 pm
- Laying out how ADCs combine the strengths of small and large molecules, thereby posing novel analytical challenges
- Explaining how analytics are key in gauging the heterogeneity and complexity of ADCs
- Undergoing a multidisciplinary approach required to evaluate the impact on safety and efficacy of any (new) ADC impurities
